KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Change in Accured Expenses (2017 - 2025)

Historic Change in Accured Expenses for Bionano Genomics (BNGO) over the last 9 years, with Q3 2025 value amounting to $721000.0.

  • Bionano Genomics' Change in Accured Expenses rose 8582.47% to $721000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.4 million, marking a year-over-year increase of 7289.05%. This contributed to the annual value of -$2.0 million for FY2024, which is 2101.51% up from last year.
  • Latest data reveals that Bionano Genomics reported Change in Accured Expenses of $721000.0 as of Q3 2025, which was up 8582.47% from -$1.3 million recorded in Q2 2025.
  • Bionano Genomics' Change in Accured Expenses' 5-year high stood at $3.5 million during Q3 2022, with a 5-year trough of -$5.3 million in Q2 2024.
  • In the last 5 years, Bionano Genomics' Change in Accured Expenses had a median value of -$443000.0 in 2022 and averaged -$67947.4.
  • In the last 5 years, Bionano Genomics' Change in Accured Expenses skyrocketed by 68010.9% in 2021 and then plummeted by 107310.34% in 2022.
  • Quarter analysis of 5 years shows Bionano Genomics' Change in Accured Expenses stood at -$145000.0 in 2021, then crashed by 1073.1% to -$1.7 million in 2022, then tumbled by 105.11% to -$3.5 million in 2023, then soared by 91.34% to -$302000.0 in 2024, then soared by 338.74% to $721000.0 in 2025.
  • Its last three reported values are $721000.0 in Q3 2025, -$1.3 million for Q2 2025, and -$488000.0 during Q1 2025.